Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infigratinib in FGFR-altered gastric/GEJ cancer and other advanced solid tumors
CTR20210275Phase 2Completed
- Sponsor
- QED Therapeutics
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of infigratinib in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and Nonhematologic neoplasms (2 cohorts), sponsored by QED Therapeutics. Primary endpoint: Objective response rate (ORR). Started Feb 2021; status: completed.
02
Drugs
infigratinib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaNonhematologic neoplasms
Beyond the preview
Go deeper on CTR20210275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210275.